Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (22,690,342)	$ (9,751,311)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	57,808	55,319
Stock-based compensation	6,989,942	2,610,412
Provision for losses on accounts receivable	50,079	0
Changes in operating assets and liabilities:
Accounts receivable	(96,225)	12,226
Insurance deposits	(1,462,171)	(749,454)
Other current assets	(477,574)	(51,154)
Accounts payable	1,420,333	596,840
Accrued liabilities	1,918,592	1,159,323
Insurance reserve	(149,430)	188,223
Deferred revenues	(33,240)	(10,564)
Net cash used in operating activities	(14,472,228)	(5,940,140)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	29,727,500	72,160
Offering costs associated with public offering	(2,126,305)	0
Proceeds from exercise of stock options	159,521	0
Proceeds from note payable	0	2,004,175
Principal repayment on note payable	0	(5,000)
Proceeds from exercise of warrants	124,540	0
Net cash provided by financing activities	27,885,256	2,071,335
Increase (decrease) in cash, cash equivalents and restricted cash	13,413,028	(3,868,805)
Cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash - beginning of period	4,923,515	10,657,140
Cash, cash equivalents and restricted cash - end of period	18,336,543	6,788,335
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets
Cash and cash equivalents	16,743,483	6,788,335
Restricted cash	1,593,060	0
Total cash, and cash equivalents and restricted cash to the consolidated balance sheets	18,336,543	6,788,335
Supplemental disclosures of cash flow information:
Interest expense	0	19
Income taxes	$ 800	$ 800